Tempus AI CEO Eric Lefkofsky sells $7 million in shares

Eric Lefkofsky, CEO and Chairman of Tempus AI, Inc. (NASDAQ:TEM), not too long ago bought shares price roughly $7,045,334, in response to an SEC submitting. The transactions occurred on December 18, 2024, with the sale costs starting from $37.34 to $39.38 per share. The sale comes because the inventory has skilled a major 13% decline over the previous week, in response to InvestingPro information. Following these transactions, Lefkofsky retains important holdings within the firm by way of varied entities, together with Blue Media, LLC and Grey Media, LLC. The gross sales have been made beneath a pre-established buying and selling plan. The $5.2 billion market cap firm presently trades close to its InvestingPro Honest Worth, sustaining a strong liquidity place with a present ratio of two.69 and exhibiting robust income development of 32% year-over-year. InvestingPro subscribers can entry 6 extra key insights about Tempus AI’s monetary well being and market place.

In different current information, Tempus AI has skilled important adjustments in its inventory worth targets following its newest earnings report and strategic acquisition of genetics agency Ambry. Piper Sandler raised its worth goal from $40 to $70, sustaining a Impartial ranking. Stifel downgraded the inventory from Purchase to Maintain, however elevated the worth goal to $65. Needham raised its inventory worth goal to $56, holding its Purchase ranking.

Tempus AI’s acquisition of Ambry Genetics is considered as a key strategic transfer, doubtlessly providing rapid genomics capabilities and future alternatives in information and purposes. The corporate has additionally partnered with Avacta Therapeutics to advance oncology drug growth utilizing AI, granting Avacta entry to Tempus’s complete multimodal datasets.

Additional, Tempus AI’s Tempus ECG-AF machine, which makes use of synthetic intelligence to determine sufferers at larger danger of atrial fibrillation/flutter, not too long ago obtained FDA clearance. These are among the many current developments surrounding Tempus AI.

This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.